Edoxaban: a focused review of its clinical pharmacology.
about
Edoxaban in venous thromboembolism and stroke prevention: an appraisalManagement of Venous Thromboembolism: Recent Advances in Oral Anticoagulation TherapyPerioperative venous thromboembolic disease and the emerging role of the novel oral anticoagulants: an analysis of the implications for perioperative managementEdoxaban.The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulantsStroke Prevention in Atrial Fibrillation - Outcomes and Future Directions.Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.The WATCHMAN device for stroke prophylaxis in atrial fibrillation: an evolving niche.Safety and efficacy of target-specific anticoagulants in patients with venous thromboembolism.Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation.Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review.Trends in oral anticoagulant use in Qatar: a 5-year experience.Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation.The challenges and limitations of widespread direct oral anticoagulant treatment: practical suggestions for their best use.Edoxaban in patients with atrial fibrillation.Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.Newer Oral Anticoagulants: Stroke Prevention and Pitfalls.Upstream versus downstream thrombin inhibition.Secondary prevention in non-valvular atrial fibrillation patients: a practical approach with edoxaban.Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure.The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review.Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis.Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal.Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors.Anticoagulant and Antiplatelet Management for Spinal Procedures: A Prospective, Descriptive Study and Interpretation of Guidelines.Appropriateness of Dabigatran and Rivaroxaban Prescribing in Qatar: A 5-Year Experience.Prothrombin time-international normalized ratio is a useful marker for edoxaban efficacy in preventing venous thromboembolism after total knee arthroplasty.Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome.Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation.Direct acting oral anticoagulant: Bench to bedside.
P2860
Q26751263-00A62B1A-712D-4019-B946-BB3B017E9933Q26766303-6BA9EF19-0F41-4ABC-A2EE-9E4852547A59Q26781790-70196BCA-CD8A-4133-A953-3F61930B12A6Q36109959-5E9C4B36-B73C-4154-832E-FF08D5C51ECCQ36396649-5F95CE16-7669-4C2B-8EF4-5248FE293911Q36458805-E519AB33-AE20-43B7-B1AF-9B262287092EQ38269003-CF09CA7D-31F9-43D2-B6F2-0A83E4092462Q38307591-5557C9BA-F49D-4792-97DF-C107986CF8C8Q38329669-BB597F2D-8711-4D39-802F-B65438C441CAQ38386660-94DD15A4-C7B5-46CA-A98C-8B5A76319EA7Q38388643-FDC10248-087F-48A2-8F9B-0AC67DC3BF71Q38403042-C834204A-7801-4FCC-8565-56C46ECEAC2CQ38630768-2967165D-8C83-4153-BAB1-92A789F29659Q38647787-F2B0615A-34F8-4794-B1C0-1969798A2E4CQ38664920-77FEE3CD-E94C-4D77-AD90-4D703A67C6E0Q38672876-CA0FCFF1-65CC-4899-94FA-1B14FE586B5FQ38685824-B6EE38BD-648A-4F3C-9C95-9B7444E04BC3Q38819152-FBE0DD03-916F-44D2-A3C0-79E7FBEEF3C2Q38878032-250BEDA8-3C02-4D3B-9477-1F695F484CF0Q38941069-0C100186-FEF3-4F3E-8387-B90E278241CCQ38944344-CE38F7CC-2F3B-4E2D-8066-28D9DA409632Q39000594-AB5ACE88-DF74-4FA3-A86F-9F6EB50016FFQ39233249-4A541CAD-F43A-457B-9938-ADFC7C237FE7Q39240697-B12F99C2-404F-4DB2-B78A-E5ECA19127ACQ39452481-7F638F3C-CCC1-40B7-BD52-489DCB86C453Q41125977-B6A60747-0D2A-4D9B-895C-0C3CA7ADC10CQ46677380-DA030629-386D-4851-856F-FFD934C865DBQ47864472-C3915679-5BE0-4703-AD9F-6294C23A394DQ48611351-042538FB-7C13-4294-9828-4923FA430AD4Q48774020-D141FE23-53E9-45B4-BBD6-1BE9CAEBE440Q52625566-E4D563E8-24B6-4897-AB7E-A17E970F0CDFQ54961174-0CFD2C45-EDA0-4F7B-919D-F123D5886E85Q55692305-DE8EF2D5-A9F8-4B21-9778-2FB27311818E
P2860
Edoxaban: a focused review of its clinical pharmacology.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Edoxaban: a focused review of its clinical pharmacology.
@en
type
label
Edoxaban: a focused review of its clinical pharmacology.
@en
prefLabel
Edoxaban: a focused review of its clinical pharmacology.
@en
P2860
P356
P1476
Edoxaban: a focused review of its clinical pharmacology.
@en
P2093
Giancarlo Agnelli
P2860
P304
P356
10.1093/EURHEARTJ/EHU181
P577
2014-05-08T00:00:00Z